Literature DB >> 9533479

Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey.

G Bonfiglio1, V Carciotto, G Russo, S Stefani, G C Schito, E Debbia, G Nicoletti.   

Abstract

In order to assess the current level of resistance to widely used antipseudomonal antibiotics in clinical isolates of Pseudomonas aeruginosa, a national survey was undertaken. Fifteen hospitals throughout Italy participated in the study. The University of Catania tested the antibiotic susceptibility of 1005 consecutive clinically significant P. aeruginosa collected from March to June 1995. Lack of susceptibility, according to NCCLS breakpoints, was at the following rates: meropenem, 9.1%; imipenem, 19.3%; ceftazidime, 13.4%; carbenicillin, 27.3%; piperacillin, 12%; ticarcillin/clavulanic acid, 22.8%; amikacin, 10.6%; and ciprofloxacin, 31.9%. About half of the isolates (44.4%) were not susceptible to at least one of the antibiotics tested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533479     DOI: 10.1093/jac/41.2.307

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group.

Authors:  E Bouza; F Garcia-Garrote; E Cercenado; M Marin; M S Diaz
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.

Authors:  F Luzzaro; E Mantengoli; M Perilli; G Lombardi; V Orlandi; A Orsatti; G Amicosante; G M Rossolini; A Toniolo
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 3.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

4.  In vitro management of hospital Pseudomonas aeruginosa biofilm using indigenous T7-like lytic phage.

Authors:  Sangeeta Ahiwale; Nilofer Tamboli; Kiran Thorat; Rajendra Kulkarni; Hans Ackermann; Balasaheb Kapadnis
Journal:  Curr Microbiol       Date:  2010-08-14       Impact factor: 2.188

5.  Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.

Authors:  Giovanni Pietro Gesu; Federico Marchetti; Laura Piccoli; Annalisa Cavallero
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

6.  Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa.

Authors:  B Segatore; D Setacci; M Perilli; N Franceschini; A De Santis; F Marchetti; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

7.  Serial granulocyte transfusions as a treatment for sepsis due to multidrug-resistant Pseudomonas aeruginosa in a neutropenic patient.

Authors:  Ying-Wei Lin; Souichi Adachi; Ken-Ichiro Watanabe; Katsutsugu Umeda; Tatsutoshi Nakahata
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

8.  Antibiotic synergy interaction against multidrug-resistant Pseudomonas aeruginosa isolated from an abattoir effluent environment.

Authors:  Etinosa O Igbinosa; Emmanuel E Odjadjare; Isoken H Igbinosa; Phillips O Orhue; May N O Omoigberale; Napoleon I Amhanre
Journal:  ScientificWorldJournal       Date:  2012-04-26

9.  Prevalence of Pseudomonas aeruginosa in post-operative wound infection in a referral hospital in Haryana, India.

Authors:  K Prabhat Ranjan; Neelima Ranjan; Satish K Bansal; D R Arora
Journal:  J Lab Physicians       Date:  2010-07

10.  Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa isolated from patients of lower respiratory tract infections.

Authors:  Anab Fatima; Syed Baqir Naqvi; Sheikh Abdul Khaliq; Shaheen Perveen; Sabahat Jabeen
Journal:  Springerplus       Date:  2012-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.